3. Duplicative Therapy

The use of two or more serotonin 5-HT₃ receptor antagonists concurrently is not justified due to the potentially increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest). There are no additional therapeutic benefits when serotonin 5-HT₃ receptor antagonists are used in combination. Patient profiles documenting receipt of multiple serotonin 5-HT₃ receptor antagonists will be reviewed.